For the quarter ending 2025-09-30, PACB had $1,664K increase in cash & cash equivalents over the period. -$18,621K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -38,000 | -468,005 |
| Depreciation | 2,461 | 7,790 |
| Amortization of intangible assets | 1,020 | 367,409 |
| Amortization of right-of-use assets | 921 | 2,162 |
| Share-based compensation expense | 10,984 | 21,096 |
| Impairment charges | 0 | 15,000 |
| Accretion of discount and amortization of premium on marketable securities, net | 923 | 2,982 |
| Change in the estimated fair value of contingent consideration | 0 | -18,700 |
| Inventory provision | 1,226 | 8,542 |
| Deferred income taxes | 0 | -546 |
| Other | -397 | -1,059 |
| Accounts receivable, net | -1,641 | 4,733 |
| Inventory, net | 1,058 | 3,868 |
| Prepaid expenses and other assets | -988 | -6,809 |
| Accounts payable | 1,266 | -505 |
| Accrued expenses | 1,011 | -2,407 |
| Deferred revenue | -123 | 808 |
| Operating lease liabilities | 1,069 | -1,730 |
| Other liabilities | -1,587 | -632 |
| Net cash used in operating activities | -18,707 | -73,433 |
| Purchases of property and equipment | -86 | 1,939 |
| Purchases of intangible assets | 0 | 5,000 |
| Purchases of investments | 65,825 | 117,992 |
| Sales of investments | 0 | - |
| Maturities of investments | 84,641 | 195,448 |
| Net cash provided by investing activities | 18,902 | 70,517 |
| Proceeds from issuance of common stock from equity plans | 1,469 | 1,959 |
| Notes payable principal payoff | 0 | 0 |
| Net cash provided by financing activities | 1,469 | 1,959 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 1,664 | -957 |
| Cash and cash equivalents at beginning of period | 57,592 | - |
| Cash and cash equivalents at end of period | 58,299 | - |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)